Shares of Eli Lilly And Company LLY announced that its Chief Financial Officer, Anat Ashkenazi, has resigned to pursue a new career. Gordon Brooks has been appointed as the interim CFO, effective July 15 2024. The company is actively searching for a permanent replacement.
What Else: Additionally, Eli Lilly’s shares are being closely watched due to a circulating article highlighting a high number of patients quitting Ozempic, a weight loss drug, due to severe side effects. This issue has impacted the broader market sentiment around weight loss medications, with lawsuits alleging severe side effects like stomach paralysis and blindness according to DailyMail.
LLY Price Action: Eli Lilly and Company shares were slightly up, trading 0.80% higher at $940.00 at the time of writing, according to Benzinga pro.
See Also: Spotify’s Long-Term Growth and Pricing Power Set to Boost Revenue: Analyst
Photo by rafapress on Shutterstock.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
